PaxVax Announces New Commercial Senior Leadership Appointments

New Hires Expand Senior Management Team Ahead of Anticipated Cholera Vaccine Launch

MENLO PARK and SAN DIEGO – MARCH 3, 2014 – PaxVax Inc., a specialty vaccine company focused on travelers and biodefense markets with a social mission to ensure global access to its vaccines, today announced the expansion of its commercial leadership team, including appointments of: Linda Rubinstein as Chief Financial Officer; Piers Whitehead as Chief Corporate Development Officer; and Thomas Yonker as Vice President of Project Management.

Pages

Cholera

18.97
-72.29

Anthrax

40.71
-74.01

Typhoid

21.00
78.00

Hepatitis A

39.92
32.83

H5N1, Dengue

& HIV

-0.78
113.92

for protection wherever you are and wherever you go

PaxVax is a fully integrated specialty vaccine company committed to developing and commercializing innovative vaccines against infectious diseases.

PaxVax: Better Vaccines

37.44
-122.14
Subscribe to PaxVax - Socially Responsible Vaccines RSS